Lecanemab, the first drug with effects against Alzheimer's in decades, has sparked debate. Several countries approved it, but the UK criticized its modest impact relative to costs.
The EMA advised against lecanemab, suggesting its 27% progression reduction is outweighed by risks like brain hemorrhages and patient fatalities. This divided the medical community.
Patient associations welcome lecanemab, viewing it as a beacon of hope for early-stage Alzheimer's patients, despite the harsh reality that most will not benefit.
International researchers have openly urged Europe to reconsider its stance on lecanemab, arguing it offers life-changing potential while the EMA denies patients access to this option.
[
Collection
]
[
|
...
]